Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinicResearch in context

Summary: Background: The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potent...

Full description

Bibliographic Details

Published in:	EBioMedicine
Main Authors:	Amanda Cano, María Capdevila, Raquel Puerta, Javier Arranz, Laura Montrreal, Itziar de Rojas, Pablo García-González, Claudia Olivé, Fernando García-Gutiérrez, Oscar Sotolongo-Grau, Adelina Orellana, Nuria Aguilera, Maribel Ramis, Maitee Rosende-Roca, Alberto Lleó, Juan Fortea, Juan Pablo Tartari, Asunción Lafuente, Liliana Vargas, Alba Pérez-Cordón, Nathalia Muñoz, Ángela Sanabria, Montserrat Alegret, Xavier Morató, Lluís Tárraga, Victoria Fernández, Marta Marquié, Sergi Valero, Daniel Alcolea, Mercè Boada, Agustín Ruiz
Format:	Article
Language:	English
Published:	Elsevier 2024-10-01
Subjects:	Plasma biomarkers pTau181 Alzheimer's disease Prodromal AD Mild cognitive impairment Real-world cohort
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396424003815